CD19 and acute lymphoblastic leukemia: CD19 antigen was commonly selected in CAR-T treatment of B cell hematologic malignancies and got a response of 80% overall response rate (ORR) in lymphomas (2, 4) and higher than 90% ORR in B acute lymphocytic leukemia (B-ALL) patients (5) with controllable toxicities.